Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of therapeutics for liver and cardiometabolic diseases. The company operates within the biotechnology and pharmaceutical research industry, with a primary emphasis on addressing conditions with significant unmet medical needs, particularly nonalcoholic steatohepatitis (NASH) and related metabolic disorders. Galmed does not currently generate product revenue and is primarily funded through equity financing and research activities.
The company’s core asset historically has been Aramchol, an orally administered small-molecule drug candidate designed to reduce liver fat content and fibrosis by modulating fatty acid metabolism. Galmed’s strategic positioning has centered on targeting liver disease through metabolic pathways rather than inflammatory or immune-based mechanisms, which differentiates it from some competitors. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Israel. Over time, the company transitioned from early-stage research into late-stage clinical development, including a Phase 3 clinical program for NASH, which significantly shaped its corporate strategy and capital allocation.
Business Operations
Galmed’s operations are organized around a single reportable segment focused on drug research and development. Its activities include preclinical research, clinical trial management, regulatory engagement, and intellectual property maintenance. The company does not manufacture or commercialize products and relies on third-party contract research organizations (CROs) and clinical trial sites to conduct studies.
Operations are primarily international in scope, with clinical trials conducted in multiple countries, including the United States, Europe, and Israel. Galmed controls proprietary technology related to fatty acid bile acid conjugates, which underpins Aramchol and related compounds. As of publicly available disclosures, Galmed has not reported any material commercial partnerships, joint ventures, or revenue-generating subsidiaries, and its activities remain focused on advancing or reassessing its clinical development pipeline.
Strategic Position & Investments
Galmed’s strategic direction has historically centered on advancing Aramchol as a potential treatment for NASH, a large and competitive therapeutic market. The company invested heavily in late-stage clinical trials, including a global Phase 3 study, representing its most significant use of capital and strategic focus. Following mixed or unfavorable clinical outcomes, Galmed has publicly indicated efforts to evaluate alternative development pathways, potential pipeline expansion, or strategic transactions.
The company has not disclosed a diversified portfolio of subsidiaries or marketed products, and its investments have been concentrated in internal research and development rather than acquisitions. Galmed has also explored emerging areas within hepatology and cardiometabolic disease, although details regarding new clinical candidates or technologies remain limited. Where future strategy beyond Aramchol has been discussed, available public information is limited and data inconclusive based on available public sources.
Geographic Footprint
Galmed Pharmaceuticals Ltd. is headquartered in Israel, which serves as the center for corporate management and scientific oversight. The company maintains a significant operational presence in the United States, primarily related to clinical development activities, regulatory interactions, and capital markets, as its ordinary shares are publicly traded on a U.S. exchange.
Its clinical and research footprint extends across North America, Europe, and parts of the Middle East, reflecting the multinational nature of its clinical trials. While Galmed does not maintain large physical infrastructures outside Israel, its international influence is derived from trial execution, regulatory engagement, and investor participation across multiple regions.
Leadership & Governance
Galmed is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development. The leadership has emphasized a strategy grounded in scientific rigor, regulatory compliance, and capital discipline, particularly given the risks associated with late-stage drug development in competitive therapeutic areas.
Key executives include:
- Allen Baharaff – President and Chief Executive Officer
- Yiftach Zurr – Chief Financial Officer
- Dr. Zvi Sheiner – Vice President of Research and Development
- Dr. Galit Livnat – Vice President of Clinical Operations
The company is governed by a board of directors that provides oversight of strategy, risk management, and shareholder interests. Galmed’s governance framework aligns with public company requirements and emphasizes compliance with applicable securities and corporate governance regulations.